Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?
作者信息
Lu Cuicui, Hou Ning
机构信息
Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
出版信息
Front Pharmacol. 2020 Sep 3;11:01304. doi: 10.3389/fphar.2020.01304. eCollection 2020.
Abstract
摘要
相似文献
1
Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?2019冠状病毒病患者的皮肤色素沉着：多粘菌素B是罪魁祸首吗？
Front Pharmacol. 2020 Sep 3;11:01304. doi: 10.3389/fphar.2020.01304. eCollection 2020.
2
Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.静脉注射多黏菌素B治疗后出现的皮肤色素沉着与黑素细胞激活及炎症过程有关。
J Clin Pharm Ther. 2017 Oct;42(5):573-578. doi: 10.1111/jcpt.12543. Epub 2017 May 11.
3
Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.多粘菌素B引起的皮肤色素沉着过度：1例罕见病例报告及文献复习
BMC Pharmacol Toxicol. 2018 Jul 4;19(1):41. doi: 10.1186/s40360-018-0226-1.
4
Polymyxin B-Induced Skin Hyperpigmentation.多黏菌素B引起的皮肤色素沉着过度。
Case Rep Med. 2020 Sep 18;2020:6461329. doi: 10.1155/2020/6461329. eCollection 2020.
5
Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.静脉注射多粘菌素B治疗后获得性皮肤色素沉着：一项队列研究。
Pigment Cell Melanoma Res. 2016 May;29(3):388-90. doi: 10.1111/pcmr.12468. Epub 2016 Mar 17.
6
Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.多粘菌素B相关弥漫性色素沉着患者色素性病变的组织病理学发现及自然肤色恢复情况
Int J Antimicrob Agents. 2016 Nov;48(5):579-580. doi: 10.1016/j.ijantimicag.2016.08.010. Epub 2016 Sep 30.
7
Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B.
Clin Infect Dis. 2007 Jul 1;45(1):136-8. doi: 10.1086/518706.
8
Pigmentary mosaicism: a review of original literature and recommendations for future handling.色素镶嵌症：原始文献回顾与未来处理建议
Orphanet J Rare Dis. 2018 Mar 5;13(1):39. doi: 10.1186/s13023-018-0778-6.
9
Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.多黏菌素 B 的临床疗效：一项静脉治疗患者的前瞻性研究。
J Clin Pharm Ther. 2019 Jun;44(3):415-419. doi: 10.1111/jcpt.12801. Epub 2019 Jan 21.
10
A newly formulated topical triple-antibiotic ointment minimizes scarring.一种新配制的局部用三联抗生素软膏可使疤痕最小化。
Cutis. 2000 Jun;65(6):401-4.
引用本文的文献
1
Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.体外血液吸附治疗 COVID-19 危重症患者的效果：一项叙述性综述。
Front Immunol. 2023 Feb 3;14:1074465. doi: 10.3389/fimmu.2023.1074465. eCollection 2023.
2
Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study.肺移植受者肺炎患者多粘菌素B的群体药代动力学分析、肾脏安全性及给药优化：一项前瞻性研究
Front Pharmacol. 2022 Oct 13;13:1019411. doi: 10.3389/fphar.2022.1019411. eCollection 2022.
3
Integration of protein context improves protein-based COVID-19 patient stratification.蛋白质背景信息的整合改善了基于蛋白质的新冠肺炎患者分层。
Clin Proteomics. 2022 Aug 11;19(1):31. doi: 10.1186/s12014-022-09370-0.
4
Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis.蛋白质组学反应揭示了涉及多粘菌素 B 诱导黑色素生成机制的信号通路。
Microbiol Spectr. 2022 Apr 27;10(2):e0273021. doi: 10.1128/spectrum.02730-21. Epub 2022 Apr 4.
5
'COVID nose' - A unique post-COVID pigmentary sequelae reminiscing Chik sign: A descriptive case series.
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e419-e421. doi: 10.1111/jdv.17989. Epub 2022 Feb 16.
6
COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks.COVID-19 是一种多器官侵害者：表观遗传和临床标志。
Front Immunol. 2021 Oct 8;12:752380. doi: 10.3389/fimmu.2021.752380. eCollection 2021.
7
Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.与 COVID-19 相关的皮肤科表现：对当前知识的全面综述。
J Med Virol. 2021 Oct;93(10):5756-5767. doi: 10.1002/jmv.27187. Epub 2021 Jul 16.
8
The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation.多粘菌素B和多粘菌素E在引起皮肤色素沉着方面的差异。
Front Pharmacol. 2021 Apr 16;12:647564. doi: 10.3389/fphar.2021.647564. eCollection 2021.
本文引用的文献
1
Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature.新型冠状病毒肺炎皮肤病变的临床与组织病理学特征及潜在病理机制：文献综述
Dermatopathology (Basel). 2020 Jun 30;7(1):3-16. doi: 10.3390/dermatopathology7010002.
2
Acute kidney injury in critically ill patients with COVID-19.COVID-19 重症患者的急性肾损伤。
Intensive Care Med. 2020 Jul;46(7):1339-1348. doi: 10.1007/s00134-020-06153-9. Epub 2020 Jun 12.
3
Management of acute kidney injury in patients with COVID-19.COVID-19 患者急性肾损伤的管理。
Lancet Respir Med. 2020 Jul;8(7):738-742. doi: 10.1016/S2213-2600(20)30229-0. Epub 2020 May 14.
4
Is the kidney a target of SARS-CoV-2?肾脏是否是 SARS-CoV-2 的靶器官？
Am J Physiol Renal Physiol. 2020 Jun 1;318(6):F1454-F1462. doi: 10.1152/ajprenal.00160.2020. Epub 2020 May 15.
5
Polymyxin B-induced skin hyperpigmentation.黏菌素 B 诱导的皮肤色素沉着。
Transpl Infect Dis. 2020 Oct;22(5):e13312. doi: 10.1111/tid.13312. Epub 2020 May 27.
6
COVID-19 diagnosis and management: a comprehensive review.COVID-19 的诊断与管理：全面综述。
J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.
7
Cutaneous manifestations in COVID-19: a first perspective.新型冠状病毒肺炎的皮肤表现：初步观点
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213. doi: 10.1111/jdv.16387.
8
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
9
Clinical Use of Polymyxin B.多黏菌素 B 的临床应用。
Adv Exp Med Biol. 2019;1145:197-218. doi: 10.1007/978-3-030-16373-0_14.
10
Drug-Induced Hyperpigmentation: Review and Case Series.药物诱导性色素沉着：综述与病例系列。
J Am Board Fam Med. 2019 Jul-Aug;32(4):628-638. doi: 10.3122/jabfm.2019.04.180212.
Zotero 插件